Clinical genomics,
white-labeled.
AuraGen's full report suite — pharmacogenomics, polygenic risk, skin and wellness genomics — available as a white-label product for clinics, employer health programs, and wellness brands. Powered by Intelliseq iFlow™.
⚠ Research Use Only · Not FDA-cleared or approved · All reports provided under RUO designation
Three ways to work together.
Clinic Portal
Per-patient pricing. AuraGen-branded reports. BAA included. HIPAA-compliant. Fastest to deploy — no infrastructure required from your side.
- ✓Per-patient ordering through a secure clinic dashboard
- ✓AuraGen-branded reports delivered to patient portal
- ✓HIPAA Business Associate Agreement (BAA) included
- ✓No infrastructure or IT setup required
- ✓Volume discount tiers available
- ✓Dedicated onboarding and clinical support
White-Label Reports
Your branding. AuraGen and Intelliseq pipeline. Full data sovereignty. Custom report design, portal, and patient communications branded entirely as your product.
- ✓Your logo, colors, and brand voice on every report
- ✓Custom patient portal with your domain
- ✓Full data sovereignty — patient data stays with you
- ✓AuraGen + Intelliseq pipeline handles all bioinformatics
- ✓All 7 report panels available under your brand
- ✓RUO compliance framework and legal templates included
Full iFlow™ License
A fully configurable clinical genomics platform, licensed directly from Intelliseq. Deploy AuraGen's entire reporting layer — plus Intelliseq's broader suite of secondary, tertiary, and full somatic/germline cancer pipelines — on your own infrastructure under your own brand.
- ✓Intelliseq iFlow™ deployed on your own HIPAA/GDPR-compliant server
- ✓Full secondary & tertiary NGS analysis pipelines included
- ✓Somatic and germline cancer variant calling (clinical-grade)
- ✓AuraGen consumer reports + full clinical pipeline suite
- ✓White-label everything — your brand, your portal, your reports
- ✓Fully configurable panels, thresholds, and report templates
- ✓Dedicated Intelliseq engineering and deployment support
Every panel. Available to partners.
All 7 report panels and the AuraGen Refresh subscription are available to B2B and white-label partners. Per-patient pricing on request.
CYP2D6, CYP2C19, SLCO1B1, VKORC1, DPYD — CPIC Level A. The most clinically actionable genomic report available. Drives physician referrals and statin safety conversations.
MC1R, TYR, MMP1, FLG, CYP2R1 — UV sensitivity, aging rate, barrier function. The consumer hook that drives DTC conversion and dermatology referrals.
CYP1A2, MTHFR, FADS1, ACTN3 — nutrigenomics and lifestyle genetics. Broad appeal and immediate actionability for functional medicine and nutrition practices.
GLP1R, GIPR, TCF7L2 — the only panel connecting GLP-1 pharmacogenomics to semaglutide and tirzepatide RCT data. Endocrinology and obesity medicine anchor.
CAD PRS + LDL burden + SLCO1B1 — the integrated report cardiologists need. Drives specialist referrals and medication safety conversations at the primary care level.
Endometriosis, PCOS, osteoporosis, menopause timing — the only DTC-available panel of its kind. OB/GYN, fertility clinic, and women's health practice anchor.
MC1R → melanoma PRS — the cross-panel clinical narrative. Dermatology practices can use this as a screening gateway tool with documented clinical utility (MSK 2022).
Annual re-query of existing variant data against new PRS models. Pure recurring revenue — no new sequencing, no new kits, no new patient interaction required.
The pipeline behind the reports
AuraGen is built on Intelliseq's iFlow™ platform — a fully configurable, cloud-based NGS analysis engine already deployed with DNAnexus Precision Health Cloud, reference labs, and DTC companies globally. Intelliseq secured €4.5M in funding (March 2025) to accelerate US market expansion.
Beyond AuraGen's consumer and clinical report suite, the full iFlow™ license unlocks Intelliseq's complete clinical genomics platform — including secondary and tertiary NGS analysis pipelines, somatic and germline cancer variant calling, and a white-label infrastructure layer that lets institutions deploy, brand, and monetize genomic intelligence entirely on their own terms.
Clinical & compliance questions.
Research Use Only (RUO) means AuraGen reports are not FDA-cleared diagnostic tests. Clinically, this means reports should be used to inform conversations with patients rather than as standalone diagnostic tools. All B2B partners receive an RUO compliance framework and patient disclosure templates. Many genomic tests used in clinical practice operate under RUO or LDT (Laboratory Developed Test) frameworks.
AuraGen executes a Business Associate Agreement (BAA) with all B2B clinic and institutional partners before any patient data is processed. The BAA covers data handling, breach notification, and the specific permitted uses of PHI. For white-label and full iFlow™ license partners, patient data never leaves your infrastructure, so AuraGen is not a business associate at all.
DNA upload from third-party providers is on our roadmap. Currently, reports require sequencing through an AuraGen kit to ensure sufficient variant coverage for our PRS and PGx panels. Bulk kit ordering with clinic branding is available for all partnership tiers.
Once a patient's sample arrives at our lab partner, sequencing takes approximately 3–4 weeks. Bioinformatics processing via Intelliseq iFlow™ adds approximately 4 hours. Reports are delivered simultaneously to the clinic portal and patient portal.
Yes — the white-label tier includes full custom branding: your logo, colors, domain, and patient portal. Your patients receive reports that look and feel like your product. AuraGen and Intelliseq operate in the background.
Ready to bring genomics
to your practice?
Whether you're a single-location clinic or a national health system, we'll scope the right model for your needs and patient volume. All partnerships include a BAA, RUO compliance framework, and dedicated onboarding.
All AuraGen reports provided to B2B and white-label partners are for Research Use Only (RUO) and are not FDA-cleared, CE-IVD certified, or approved for clinical diagnostic use. Partners are responsible for ensuring appropriate RUO disclosure to their end users in compliance with applicable local, state, and federal regulations. AuraGen provides RUO disclosure templates and compliance guidance as part of all partnership agreements. © 2026 AuraGen Wellness · auragenwellness.com